|
| Monday, 9 November 2020, 08:08 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| - The Content Presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference - |
TOKYO, Nov 9, 2020 - (JCN Newswire) - Sysmex Corporation and Eisai Co., Ltd. announced that the most recent data from the project to develop a method of diagnosing Alzheimer's disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually from November 4 to 7, 2020. Sysmex demonstrated on behalf of the two companies the performance of the amyloid beta (Abeta) in plasma measured on Sysmex's HISCLTM fully automated immunoassay analyzers in predicting amyloid pathology as defined by amyloid positron emission tomography (PET) imaging on the centiloid scale.(1)
The total number of those living with dementia across the world is projected to reach 82 million in 2030 and 152 million in 2050, with the total global societal cost of dementia stemming from direct medical and social care costs and lower productivity being estimated to reach 2 trillion USD in 2030.(6) In Japan, the number of those with dementia is thought to have reached approximately 4.62 million in 2012 and is projected to grow to 7.30 million in 20257, with the total societal cost of this disease is estimated to be equivalent to 4.1%8 of the gross domestic product (GDP) in 2025 (25.8 trillion yen9). Of these sufferers, those living with AD are thought to account for more than 60% of those living with dementia.(7)
It is conceivable that AD is a disease that results in synaptic dysfunction and neuronal cell death due to tau deposition in neurons triggered by Abeta aggregation on the outside of neurons. These brain changes cause cognitive impairment and psychological and behavioral symptoms, suggesting that the Abeta aggregation and accumulation inside the brain is caused by AD before the presence of cognitive impairment appears, thus, it is believed that early diagnosis and early intervention is more effective in therapies targeting Abeta. Currently, amyloid PET and Abeta ratio in cerebrospinal fluid (CSF) are used for detecting amyloid aggregates in the brain, but this puts a significant burden on patients in terms of access, costs, and their physical wellbeing.(10)
Sysmex and Eisai are working to create new diagnostic technologies for the prevention and treatment of dementia. Accordingly, the overarching aim is to contribute to the advancement of healthcare and improve the quality of life for those living with the disease and their families.
Terminology
(1) A standardization scale for integration analysis of PET SUVR values as measured by different amyloid PET imaging probes.
(2) Trained doctors qualitatively distinguish amyloid PET positive from amyloid negative subjects by visually reading images.
(3) Klunk WE et al, Alzheimer's Dementia (2014)
(4) Assesses how correlated two sets of data are based on two quantitative data distributions.
For the purpose of this analysis, Spearman's rank correlation coefficient (rs), which is a
correlation index as determined by the rankings of the two variables, was calculated.
(5) Schindler SE et al, Neurology (2019)
(6) World Alzheimer Report 2018
(7) Promotion of Comprehensive Measures against Dementia, Ministry of Health, Labour and
Welfare
(8) Study on Economic Impact of Dementia in Japan, 2014 Health Labour Sciences Research
Grant Annual Report
(9) Estimated by Sysmex based on Japan's Medium-term Economic Outlook (February 2018),
Daiwa Institute of Research
(10) Abeta is a peptide made of amino-acid residues removed from amyloid precursor protein. Many of them are Abeta1-40, which is comprised of 40-residues, and the Abeta1-40 level does not fluctuate significantly as AD progresses. Comprised of 42-residues, Abeta1-42, on the other hand, is highly cohesive and decreases in cerebrospinal fluid (CSF) from the early stages of AD. It is believed that Abeta's absolute values show individual and intrinsic variability but that the plasma Abeta1-42/Abeta1-40 ratio remains unchanged. It has also been reported that the plasma Abeta1-42/Abeta1-40 ratio in CSF shows a high correlation with amyloid PET.
About the collaboration between Sysmex and Eisai
In February 2016, Sysmex and Eisai signed a comprehensive non-exclusive agreement aimed at the development of new diagnostic tests in the field of dementia. By leveraging each other's technologies and knowledge, the objective has been to discover next-generation diagnostic reagents that will enable early diagnosis of dementia, selection of the most appropriate treatment options, and regular monitoring of the effects of such treatments. At the 12th CTAD held in December 2019, the two companies reported on the performance of the plasma Abeta ratio measured on a fully automated immunoassay system HISCL in predicting the amyloid PET scan results (sensitivity: 73%, specificity: 71% [AUC = 0.74]), thus demonstrating the potential to predict amyloid pathology in the brain using the plasma Abeta ratio.* This finding was expected to lead to the development of a simple method of diagnosing Alzheimer's disease using blood.
*https://www.sysmex.co.jp/en/news/2019/191209.html https://www.eisai.com/news/2019/news201990.html
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Apr 18, 2025 15:52 HKT/SGT |
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Apr 1, 2025 12:15 HKT/SGT |
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Mar 25, 2025 16:28 HKT/SGT |
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| Mar 25, 2025 11:21 HKT/SGT |
|
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Mar 10, 2025 19:24 HKT/SGT |
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
| Mar 5, 2025 08:09 HKT/SGT |
|
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan |
| Mar 4, 2025 16:22 HKT/SGT |
|
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia |
| Mar 3, 2025 14:41 HKT/SGT |
|
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" |
| Mar 3, 2025 12:53 HKT/SGT |
|
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease |
| Feb 28, 2025 11:31 HKT/SGT |
|
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone |
| More news >> |
 |
|
|
|
